Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and caucasian male subjects

Journal of Clinical Pharmacology

Volumn 50, Issue 7, 2010, Pages 792-802

  Jie, Ling ^a   Lyn, Sally ^a   Zhenhua Xu, ^a   Achira, Meguru ^b   Bouman Thio, Esther ^a   Shishido, Akira ^b   Ford, Joyce ^a   Shankar, Gopi ^a   Wagner, Carrie ^a   Kim, Kenneth T ^c   Davis, Hugh M ^a   Honghui Zhou, ^a  

^a CENTOCOR INC   (United States)

^b Janssen Pharmaceutical KK   (Japan)

^c West Coast Clinical Trials LLC   (United States)

Author keywords

Golimumab; Japanese; Monoclonal antibody; Pharmacokinetics; Tumor necrosis factor antagonist

Indexed keywords

GOLIMUMAB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; ALANINE TRANSAMINASE; ANTIBODIES; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; BODY MASS INDEX; COHORT STUDIES; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 77953758429     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009355162     Document Type: Article

References (31)

1. Beutler B., Cerami A. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. New York, NY: Raven Press ; 1992.
2. Brennan FM, Maini RN, Feldmann M. TNF-alpha-a pivotal role in rheumatoid arthritis ? Br J Rheumatol. 1992 ; 31: 293-298.
3. Bonifati C., Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999 ; 38: 241-251.
4. Ritchlin C., Haas-Smith SA, Hicks D., Cappuccio J., Osterland CK, Looney RJ Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998 ; 25: 1544-1552.
5. Francois RJ, Neure L., Sieper J., Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006 ; 65: 713-720.
6. Braegger CP, Nicholls S., Murch SH, Stephens S., MacDonald TT Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992 ; 339: 89-91.
7. Russo C., Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond). 2005 ; 109: 135-142.
8. Tracey D., Klareskog L., Sasso EH, Salfeld JG, Tak PP Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 ; 117: 244-279.
9. Zhou H., Jang H., Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47: 383-396.
10. Fleischmann R., Cohen S., Caldwell JR et al. Phase 1 studies evaluating the safety, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous administration of a fully human monoclonal antibody to human TNF-alpha (CNTO 148) in rheumatoid arthritis patients. Arthritis Rheum. 2004 ; 50 (suppl): S178.
11. Koleba T., Ensom MH Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006 ; 26: 813-827.
12. Wang W., Wang EQ, Balthasar JP Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008 ; 84: 548-558.
13. Xolair [package insert]. South San Francisco, Calif: Genentech ; 2008.
14. Mascelli MA, Zhou H., Sweet R., et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol. 2007 ; 47: 553-565.
15. Woodworth JR, Fike RR Nuances of drug metabolism and pharmacokinetic requirements for package submission to Japanese regulatory. In: Bonate PL, Howard DR, eds. Pharmacokinetics in Drug Development: Regulatory and Development Paradigms. Arlington, Va: AAPS Press; 2004: 265-277.
16. Iznaga-Escobar N., Mishra AK, Perez-Rodriguez R. Factors affecting pharmacokinetics of monoclonal antibodies: a review article. Methods Find Exp Clin Pharmacol. 2004 ; 26: 123-127.
17. Lobo ED, Hansen RJ, Balthasar JP Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 ; 93: 2645-2668.
18. Li JS, Baker-Smith CM, Smith PB, et al. Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. Clin Pharmacol Ther. 2008 ; 84: 315-319.
19. Myrand SP, Sekiguchi K., Man MZ, et al. Pharmacokinetics/ genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther. 2008 ; 84: 347-361.
20. Bruno R., Washington CB, Lu JF, Lieberman G., Banken L., Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005 ; 56: 361-369.
21. Kuester K., Kovar A., Lupfert C., Brockhaus B., Kloft C. Population pharmacokinetic data analysis of three phase 1 studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. Br J Cancer. 2008 ; 98: 900-906.
22. Ng CM, Lum BL, Gimenez V., Kelsey S., Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006 ; 23: 1275-1284.
23. Brambell FW, Hemmings WA, Morris IG A theoretical model of gamma-globulin catabolism. Nature. 1964 ; 203: 1352-1354.
24. Roskos LK, Davis CG, Schwab GM The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004 ; 61: 108-120.
25. Lu JF, Bruno R., Eppler S., Novotny W., Lum B., Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008 ; 62: 779-786.
26. Inman RD, Davis JC Jr, van der Heijde D., et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008 ; 58: 3402-3412.
27. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009 ; 60: 976-986.
28. Xu ZH, Wang QM, Zhuang YL, et al. Bioavailability of golimumab, an anti-tumor necrosis factor-± human monoclonal antibody, administered subcutaneously at three different injection sites in healthy subjects. Clin Pharmacol Ther. 2009 ; 85: S24.
29. Kanamaru M., Nagashima S., Uematsu T., Nakashima M. Influence of 7-day hospitalisation for phase 1 study on the biochemical laboratory tests of healthy volunteers. Jpn J Clin Pharmacol Ther. 1989 ; 20: 493-503.
30. Rosenzweig P., Miget N., Brohier S. Transaminase elevation on placebo during phase 1 trials: prevalence and significance. Br J Clin Pharmacol. 1999 ; 48: 19-23.
31. Purkins L., Love ER, Eve MD, et al. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a phase 1 unit. Br J Clin Pharmacol. 2004 ; 57: 199-208.